FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Dose modifications for treatment-related toxicities1

  • Treatment with FOLOTYN may cause mucositis, severity of which should be monitored weekly. If ≥Grade 2, omit and/or reduce dose
  • Dose omissions and/or reductions to 20 mg/m2 may be needed to manage adverse drug reactions
Dose modifications for Grade 3-4 treatment‐related toxicities

*Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0)


  • FOLOTYN Prescribing Information. Allos Therapeutics, Inc. 2012.